Skip to main content
. 2021 Feb 19;10(4):868. doi: 10.3390/jcm10040868

Figure 6.

Figure 6

Patients with evidenced disease progression: the proportion of estimations derived from observation of patients never associated with any relapses or brain MRI activity between 12 and 60 months from the prescription start. The upper pane uses the complete set of observations (green; label at y = 1 is “All”), the middle pane uses first- and second-line treatment (label at y = 1; first-line, dark brown; second-line, dark blue), and the lower pane uses the drug (label at y = 1; Fingolimod, red, FTY; Glatiramer Acetate, dark blue, GLA; Interferon, blue, INF; Natalizumab, light brown, NAT). The error bar represents the standard error estimated asp × (1 − p)/n, with p being the number of positives and n the total number of observations. DMT: disease-modifying therapy.